




*(Use as many sheets as necessary)*

Sheet	1	of	3	Attorney Docket No.	ABB1259P00381US
-------	---	----	---	---------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standards ST.16, if possible.  
<sup>6</sup> Applicant is to place a checkmark here if English language Translation is attached.



Comparable to Form PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0851-0031

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	10/807,942
				Filing Date	03/24/04
				First Named Inventor	Kristof Chwallisz
				Group Art Unit	1616
				Examiner Name	N.R. Handy
Sheet	2	of	3	Attorney Docket No.	ABB1259P00381US

**FOREIGN PATENT DOCUMENTS**

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
/N.H./ ↓		WO 99/45023	09-10-1999	Jenapharm et al.		
		EP0909764	04-21-1999	Jenapharm GmbH		
		WO 01/15679	03-08-2001	Schering AG et al.		
		WO 01/26603	04-19-2001	Schering AG et al.		
		WO 01/34126	05-17-2001	Jenapharm et al.		
		WO 01/90137	11-29-2001	Jenapharm et al.		
		WO 02/38581	05-16-2002	Jenapharm et al.		
		WO 02/38582	05-16-2002	Jenapharm et al.		
		WO 02/38583	05-16-2002	Jenapharm et al.		
		WO 03/090786	11-16-2003	Jenapharm et al.		
		WO 03/090714	11-06-2003	Jenapharm et al.		
		WO 03/090721	11-06-2003	Jenapharm et al.		
		WO 03/091272	11-06-2003	Jenapharm et al.		
	/N.H./		WO 2004/045620	06-03-2004	TAP Pharmaceutical Products Inc.	
Examiner Signature		/Nikki Handy/		Date Considered	03/22/2007	

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standards ST.16, if possible. <sup>6</sup> Applicant is to place a checkmark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) and application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

CHICAGO2290609.1  
IDLVM



Comparable to Form PTO/SB/08A (08-03)  
Approved for use through 07/31/2006. OMB 0651-0031  
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO				Application Number	10/807,942
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Filing Date	03/24/04
				First Named Inventor	Kristof Chwalisz
				Group Art Unit	1616
				Examiner Name	N.R. Handy
Sheet	3	of	3	Attorney Docket No.	ABB1259P00381US

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/N.H./		Demanno D et al., "Asoprisnil (J867): A Selective Progesterone Receptor Modulator for Gynecological Therapy," <i>Steroids</i> , 68(10-13):1019-1032 (November 2003).	
/N.H./		Chwalisz K et al., "Antiproliferative Effects of Progesterone Antagonists and Progesterone Receptor Modulators on the Endometrium", <i>Steroids</i> , 65(10-11): 741-751 (October 2000).	
/N.H./		Written Opinion mailed 10/18/2006 for PCT/US2005/009317	
/N.H./		Search Report mailed 10/18/2006 for PCT/US2005/009317	
Examiner Signature	/Nikki Handy/		Date Considered 03/22/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) and application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450.